Alnylam Pharmaceuticals Inc.
) provided an update on its pipeline and its goals for the coming
years. The company has progressed well with its 'Alnylam 5x15'
program so far, and expects six to seven genetic medicine
programs in the clinic by 2015 instead of five genetic medicine
One of the important candidates under Alnylam's 'Alnylam 5x15'
program is patisiran (ALN-TTR02), which is being developed for
the treatment of transthyretin-mediated amyloidosis (ATTR).
The candidate is currently in the phase III APOLLO study in ATTR
patients suffering from familial amyloidotic polyneuropathy
(FAP). Patisiran is also in a phase II open-label extension study
for the treatment of patients suffering from FAP. Alnylam intends
to report data from the open-label extension study once a year
with initial data expected later this year.
ALN-TTRsc, another important candidate under Alnylam's 'Alnylam
5x15' program is currently in a phase II study in ATTR patients
suffering from familial amyloidotic cardiomyopathy (FAC) or
senile systemic amyloidosis (SSA). Results from the phase II
study are expected late in the year.
Patients successfully completing the phase II study will be
eligible for an open-label extension study which is expected to
be initiated in mid-2014. Moreover, Alnylam has plans to initiate
a phase III study on ALN-TTRsc in patients suffering from TTR
cardiac amyloidosis by year end.
ACTELION LTD (ALIOF): Get Free Report
ALNYLAM PHARMA (ALNY): Free Stock Analysis
MERCK & CO INC (MRK): Free Stock Analysis
SANOFI-AVENTIS (SNY): Free Stock Analysis
To read this article on Zacks.com click here.
Apart from these candidates, Alnylam also has plans to initiate a
phase I study on ALN-AT3 (hemophilia and other rare bleeding
disorders) soon with initial results expected by year end.
Additionally, the company will file three Investigational New
Drug (IND) applications by 2015 for ALN-CC5 (complement-mediated
diseases), ALN-AS1 (hepatic porphyrias) and ALN-PCSsc for
(hypercholesterolemia). We expect investor focus remain on the
Alnylam's pipeline going forward.
Alnylam also said that it will acquire
Merck & Co. Inc.
) wholly owned subsidiary Sirna Therapeutics, Inc. for $175
million in cash and equity. Merck is also expected to receive up
to $105 million as developmental and sales milestone payments per
product along with single-digit royalties related to certain
pre-clinical candidates discovered by Merck. Alnylam will also
pay $10 million as milestone payments and single-digit royalties
for products covered by Sirna's patent estate.
Moreover, Alnylam has expanded its strategic agreement with
) for the development and commercialization of candidates for the
treatment of rare genetic diseases. As per the new agreement,
Alnylam will retain most of the product rights in North America
and Western Europe whereas Sanofi will become a major Alnylam
shareholder with a stake of approximately 12% for an investment
of $700 million.
Alnylam's collaborations with big companies like Merck and Sanofi
are encouraging. The deals will not help Alnylam to generate
revenues from royalties but it will also take its RNAi technology
outside its core focus area.
Alnylam presently carries a Zacks Rank #4 (Sell). Some
better-ranked stocks include
) with a Zacks Rank #1 (Strong Buy).